Patents by Inventor Doreen Weigelt

Doreen Weigelt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11872289
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: January 16, 2024
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • Publication number: 20230372520
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 23, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Publication number: 20230139769
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: August 1, 2022
    Publication date: May 4, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Publication number: 20210221910
    Abstract: The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 22, 2021
    Applicant: GLYCOTOPE GMBH
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK
  • Publication number: 20210187118
    Abstract: The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Publication number: 20200087410
    Abstract: The present invention pertains to humanized anti-CD40 antibodies having antigen binding properties similar to those of the parent chimeric anti-CD40 antibody and increased Fc? receptor binding affinities. In particular, the present invention is directed to humanized anti-CD40 antibodies which are useful in the treatment of cancer, infections and immunodeficiencies.
    Type: Application
    Filed: March 27, 2018
    Publication date: March 19, 2020
    Applicant: Glycotope GmbH
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Anja LOFFLER, Doreen WEIGELT, Patrick KEHLER
  • Publication number: 20180230552
    Abstract: This invention relates to a detection method for nucleic acids in samples that contain biological material, as well as to a kit having components with which the detection method can be carried out. In samples that contain biotechnologically produced biological material, for example, the detection method is suitable for detecting nucleic acids of host cells that were used for the production of the material.
    Type: Application
    Filed: September 22, 2015
    Publication date: August 16, 2018
    Inventors: Steffen Goletz, Doreen Weigelt, Jana Langthaler, Helmut Troester